Alkem Labs unit to buy up to 55% of Occlutech

Occlutech, the second-largest player in Europe's minimally invasive cardiac implants segment, posted a revenue of 49.4 million ‌for 2025. It derives about 85% of its revenue from Europe and the ​U.S.